PCM
STLN

Prelude Capital Management’s Starling Oncology STLN Stock Holding History

Prelude Capital Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,880
Closed -$41.5K – 1552
2025
Q3 		$41.5K Buy
+11,880
New +$40.7K ﹤0.01% 1110
2024
Q1 		– Sell
-19,629
Closed -$40K – 1524
2023
Q4 		$40K Sell
19,629
-30,240
-61% -$52.4K ﹤0.01% 1082
2023
Q3 		$69.8K Buy
49,869
+8,652
+21% +$8.96K ﹤0.01% 1020
2023
Q2 		$22.7K Buy
+41,217
New +$21.8K ﹤0.01% 1009

Other funds holding STLN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $413M AUM 109.83% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Prelude Capital Management's STLN Position: Q4 2025 in Review

Prelude Capital Management sold out of Starling Oncology (STLN) in Q4 2025, closing a stake of 11,880 shares — an estimated $41.5K sold.

Prelude Capital Management first reported a position in STLN in Q2 2023 and held it in 4 quarters. The position peaked at $69.8K in Q3 2023. 117 funds tracked by Wall St. Rank hold STLN as of Q4 2025.

  • Prelude Capital Management reported no remaining Starling Oncology position as of Q4 2025 after selling out during the quarter.
  • Prelude Capital Management sold 11,880 Starling Oncology shares in Q4 2025, an estimated $41.5K.
  • Prelude Capital Management first reported a position in Starling Oncology in Q2 2023 and held it in 4 quarters.
  • Prelude Capital Management's Starling Oncology position peaked at $69.8K in Q3 2023.
  • 117 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2025.

Based on Prelude Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.